FI905770A0 - Uusia isoindolonijohdannaisia niiden valmistus ja käyttö - Google Patents

Uusia isoindolonijohdannaisia niiden valmistus ja käyttö

Info

Publication number
FI905770A0
FI905770A0 FI905770A FI905770A FI905770A0 FI 905770 A0 FI905770 A0 FI 905770A0 FI 905770 A FI905770 A FI 905770A FI 905770 A FI905770 A FI 905770A FI 905770 A0 FI905770 A0 FI 905770A0
Authority
FI
Finland
Prior art keywords
preparation
derivatives
isoindolone derivatives
new
new isoindolone
Prior art date
Application number
FI905770A
Other languages
English (en)
Swedish (sv)
Other versions
FI94627B (fi
FI94627C (fi
FI905770A (fi
Inventor
Marie-Christine Dubroeucq
Claude Moutonnier
Jean-Francois Peyronel
Michel Tabart
Alain Truchon
Original Assignee
Rhone Poulenc Sante
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Sante filed Critical Rhone Poulenc Sante
Publication of FI905770A0 publication Critical patent/FI905770A0/fi
Publication of FI905770A publication Critical patent/FI905770A/fi
Publication of FI94627B publication Critical patent/FI94627B/fi
Application granted granted Critical
Publication of FI94627C publication Critical patent/FI94627C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI905770A 1989-11-23 1990-11-22 Uusia isoindolonijohdannaisia niiden valmistus ja käyttö FI94627C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8915407A FR2654726B1 (fr) 1989-11-23 1989-11-23 Nouveaux derives de l'isoindolone et leur preparation.
FR8915407 1989-11-23

Publications (4)

Publication Number Publication Date
FI905770A0 true FI905770A0 (fi) 1990-11-22
FI905770A FI905770A (fi) 1991-05-24
FI94627B FI94627B (fi) 1995-06-30
FI94627C FI94627C (fi) 1995-10-10

Family

ID=9387708

Family Applications (1)

Application Number Title Priority Date Filing Date
FI905770A FI94627C (fi) 1989-11-23 1990-11-22 Uusia isoindolonijohdannaisia niiden valmistus ja käyttö

Country Status (23)

Country Link
US (1) US5112988A (fi)
EP (1) EP0430771B1 (fi)
JP (1) JPH03176468A (fi)
KR (1) KR910009660A (fi)
AT (1) ATE108774T1 (fi)
AU (1) AU635984B2 (fi)
CA (1) CA2030570A1 (fi)
DE (1) DE69010851T2 (fi)
DK (1) DK0430771T3 (fi)
ES (1) ES2057488T3 (fi)
FI (1) FI94627C (fi)
FR (1) FR2654726B1 (fi)
HU (1) HU214574B (fi)
IE (1) IE64737B1 (fi)
IL (1) IL96447A (fi)
NO (1) NO174148C (fi)
NZ (1) NZ236175A (fi)
PL (2) PL164973B1 (fi)
PT (1) PT95983B (fi)
RU (1) RU2104269C1 (fi)
SK (1) SK278474B6 (fi)
YU (1) YU47437B (fi)
ZA (1) ZA909370B (fi)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676442B1 (fr) * 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveau derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2688219B1 (fr) 1992-03-03 1994-07-08 Sanofi Elf Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant.
FR2689889B1 (fr) * 1992-04-10 1994-06-10 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole, et leur preparation.
US5830854A (en) * 1992-12-14 1998-11-03 Merck Sharp & Dohme, Limited Method of treating cystic fibrosis using a tachykinin receptor antagonist
FR2703679B1 (fr) * 1993-04-05 1995-06-23 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2710913B1 (fr) * 1993-10-07 1995-11-24 Rhone Poulenc Rorer Sa Nouveaux dérivés de perhydroisoindole, leur préparation et les compositions pharmaceutiques qui les contiennent.
TW365603B (en) * 1993-07-30 1999-08-01 Rhone Poulenc Rorer Sa Novel perhydroisoindole derivatives, their preparation and pharmaceutical compositions which contain them
FR2709752B1 (fr) * 1993-07-30 1995-10-06 Rhone Poulenc Rorer Sa Nouveaux dérivés de perhydroisoindole, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5543530A (en) * 1993-12-23 1996-08-06 Ortho Pharmaceutical Corporation 4-arylisoindole analgesics
FR2728165A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728169A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
FR2729954B1 (fr) 1995-01-30 1997-08-01 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
FR2755013B1 (fr) * 1996-10-29 1998-11-27 Rhone Poulenc Rorer Sa Nouvelle application therapeutique des antagonistes de la substance p
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
ES2304984T3 (es) 1999-11-03 2008-11-01 Amr Technology, Inc. Tetra-hidroisoquinolinas de sustitucion arilica y heteroarilica y su utilizacion para bloquear la recaptacion de norepinefrina, dopamina y serotonina.
CN100430401C (zh) 2000-07-11 2008-11-05 Amr科技公司 新的4-苯基取代的四氢异喹啉类化合物及其治疗用途
CN101119969B (zh) 2004-07-15 2014-04-09 阿尔巴尼分子研究公司 芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和血清素的重摄取的应用
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
JP5258561B2 (ja) 2005-07-15 2013-08-07 アルバニー モレキュラー リサーチ， インコーポレイテッド アリール置換およびヘテロアリール置換テトラヒドロベンズアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
SI2805945T1 (sl) 2007-01-10 2019-09-30 Msd Italia S.R.L. Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP)
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
ES2446971T3 (es) 2009-05-12 2014-03-11 Albany Molecular Research, Inc. Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso
ES2662072T3 (es) 2009-05-12 2018-04-05 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y uso de la misma
ES2528404T3 (es) 2009-05-12 2015-02-10 Bristol-Myers Squibb Company Formas cristalinas de (S)-7-([1,2,4]triazol[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y sus usos
WO2011046771A1 (en) 2009-10-14 2011-04-21 Schering Corporation SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
US8653025B2 (en) * 2010-01-27 2014-02-18 AB Pharma Ltd. Polyheterocyclic compounds highly potent as HCV inhibitors
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP3587574B1 (en) 2010-08-17 2022-03-16 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP2632472B1 (en) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012145471A1 (en) 2011-04-21 2012-10-26 Merck Sharp & Dohme Corp. Insulin-like growth factor-1 receptor inhibitors
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
US9233979B2 (en) 2012-09-28 2016-01-12 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
PL2925888T3 (pl) 2012-11-28 2018-03-30 Merck Sharp & Dohme Corp. Kompozycje i sposoby do stosowania w leczeniu nowotworów
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2858314A (en) * 1954-06-07 1958-10-28 Georgian Vlasios Hydrocarbazolenines
US4042707A (en) * 1976-02-19 1977-08-16 E. I. Du Pont De Nemours And Company 3α-Arylhydroisoindoles
US4494547A (en) * 1981-03-30 1985-01-22 North Carolina Central University 2H-isoindolediones, their synthesis and use as radiosensitizers

Also Published As

Publication number Publication date
AU6682890A (en) 1991-05-30
NZ236175A (en) 1993-03-26
SK580690A3 (en) 1997-07-09
IL96447A0 (en) 1991-08-16
KR910009660A (ko) 1991-06-28
NO174148B (no) 1993-12-13
FI94627B (fi) 1995-06-30
HUT55756A (en) 1991-06-28
DK0430771T3 (da) 1994-08-29
AU635984B2 (en) 1993-04-08
DE69010851T2 (de) 1994-11-24
ES2057488T3 (es) 1994-10-16
PL164973B1 (pl) 1994-10-31
IE64737B1 (en) 1995-09-06
ZA909370B (en) 1991-10-30
EP0430771A1 (fr) 1991-06-05
YU223590A (sh) 1993-05-28
NO905067D0 (no) 1990-11-22
DE69010851D1 (de) 1994-08-25
PT95983A (pt) 1991-09-13
HU907249D0 (en) 1991-05-28
JPH03176468A (ja) 1991-07-31
FI94627C (fi) 1995-10-10
PT95983B (pt) 1998-01-30
NO174148C (no) 1994-03-23
RU2104269C1 (ru) 1998-02-10
FI905770A (fi) 1991-05-24
IL96447A (en) 1995-03-15
NO905067L (no) 1991-05-24
CA2030570A1 (fr) 1991-05-24
FR2654726A1 (fr) 1991-05-24
FR2654726B1 (fr) 1992-02-14
EP0430771B1 (fr) 1994-07-20
SK278474B6 (en) 1997-07-09
YU47437B (sh) 1995-03-27
PL164955B1 (en) 1994-10-31
ATE108774T1 (de) 1994-08-15
IE904234A1 (en) 1991-06-05
US5112988A (en) 1992-05-12
PL287908A1 (en) 1991-12-02
HU214574B (hu) 1998-04-28

Similar Documents

Publication Publication Date Title
FI905770A0 (fi) Uusia isoindolonijohdannaisia niiden valmistus ja käyttö
RU92004482A (ru) Производные изоиндола
FI935072A0 (fi) Nya perhydroisoindoler och deras framstaellning
MX9301986A (es) Derivados de perhidroisoindol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
FI915970A0 (fi) Laekemedel, som aer nyttiga vid vaord av cancer och som har antihistaminegenskaper.
DK327286D0 (da) Indolcarboxamidderivater og salte deraf, deres fremstilling og anvendelse som laegemidler samt mellemprodukter til deres fremstilling
FI861324A (fi) Nya (4.2.0) bicyclooktanderivat, som har vaerdefulla terapeutiska egenskaper.
FI861934A (fi) Nya isoxazolderivat, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska preparat.
ES531318A0 (es) Procedimiento para la obtencion de derivados quinolinicos
ES2042727T3 (es) Acidos 1,3,4,9-tetrahidropirano(3,4-b)indol-1-acetico.
DK0424248T3 (da) 20,21-dinoreburnamein med substitution i 15-stillingen, fremgangsmåde til deres fremstilling samt mellemprodukter til brug derved, deres anvendelse som lægemidler og præparater med indhold deraf
NZ216741A (en) 6-oxo-1,6-dihydropyridazines and pharmaceutical compositions
ES2064692T3 (es) Nuevos derivados de la 2-acetidinona 1,3,4-trisustituidas y su procedimiento de sintesis asimetrica.

Legal Events

Date Code Title Description
BB Publication of examined application
MM Patent lapsed

Owner name: RHONE-POULENC SANTE